Clinical Trials Sponsored by German Hodgkin's Lymphoma Study Group

Total 161 results

International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (RITZ)

Splenic Marginal Zone Lymphoma

Spain, Denmark, France, Norway, Switzerland, Sweden, Italy
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role (PIMENTO)

Marginal Zone Lymphoma

France, Italy, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA)

Primary Central Nervous System Lymphoma

Denmark, Finland, Italy, Israel, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Primary Mediastinal B-cell Lymphoma

Norway, United Kingdom, Italy, Switzerland, Czechia, United States, China, Argentina, Canada, Germany, Poland, Portugal, Sweden, Ukraine
International Extranodal Lymphoma Study Group (IELSG)

Completed

Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Central Nervous System Lymphoma

Germany, Italy, United Kingdom, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Withdrawn

A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis

Lymphoma, B Cell
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Terminated

Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma

Lymphoma, B-Cell

Italy
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Nodal Marginal Zone Lymphoma

United States, Switzerland, Armenia, France, Italy
International Extranodal Lymphoma Study Group (IELSG)

Recruiting

Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

China
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

Marginal Zone Lymphoma of Ocular Adnexal

Italy
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

MALT Lymphoma

Switzerland, Italy, France
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Diffuse Large B-cell Lymphoma

Netherlands, United Kingdom, Italy, Czechia
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (IELSG30)

Large B-cell Diffuse Lymphoma of Testis

Italy, Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

Splenic Marginal Zone Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma

Lymphoma, Mucosa-Associated Lymphoid Tissue

United Kingdom, France, Italy, Switzerland, Spain, Belgium
International Extranodal Lymphoma Study Group (IELSG)

Completed

A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal B-Cell Lymphoma

Italy, United Kingdom, Switzerland, Spain
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Lymphoma, B Cell

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell

Switzerland
German Breast Group
AGO Study Group

Completed

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer (GeparQuinto)

Breast Cancer

Germany
German Breast Group
AGO Study Group

Completed

Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)

Breast Cancer

Germany
West German Study Group
GlaxoSmithKline

Terminated

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Carcinoma, Ductal, Breast

Germany
West German Study Group
Agendia

Completed

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) (PRIMe)

Breast Cancer

Switzerland, Austria, Germany
German Parkinson Study Group (GPS)

Completed

STN-Stimulation Versus Best Medical Treatment in Advanced PD

Parkinson's Disease

Germany
West German Study Group
Agendia

Recruiting

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS (PROOFS)

Female Breast Cancer

Germany
German CLL Study Group
AstraZeneca

Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Chronic Lymphocytic Leukemia

Germany
West German Study Group
Celgene

Active, not recruiting

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

Breast Cancer

Germany
German CLL Study Group
Celgene

Completed

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Chronic Lymphocytic Leukemia

Germany
Lymphoma Study Association
Institute of Cancer Research, United Kingdom; Australasian Leukaemia and Lymphoma... and other collaborators

Completed

Primary Rituximab and Maintenance

Follicular Lymphoma

France, Thailand, Belgium, Spain, Argentina, Australia, Brazil, Colombia, Denmark, Netherlands, New Zealand, Peru
West German Study Group
AstraZeneca

Not yet recruiting

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)

HER2-positive Early Breast Cancer

Germany
West German Study Group
Sanofi; Amgen

Completed

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer (planB)

Primary Breast Cancer | Her2 Non-overexpressing

Germany
Gilead Sciences
German CLL Study Group

Completed

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
Gilead Sciences
German CLL Study Group

Completed

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

Germany
German Hodgkin's Lymphoma Study Group
European Organisation for Research and Treatment of Cancer - EORTC; EBMT Solid...

Unknown

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Lymphoma

Poland, Belgium, Switzerland, Netherlands, Germany, Denmark, Croatia, Portugal
Klaus Herfarth, MD
Roche Pharma AG; German Low Grade Lymphoma Study Group

Completed

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma (MIR)

Lymphoma, Malignant

Germany
West German Study Group
Roche Pharma AG

Active, not recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1)

Breast Cancer

Germany
German CLL Study Group
Janssen-Cilag Ltd.

Completed

Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression (CLL12)

Chronic Lymphocytic Leukemia

Germany
German CLL Study Group
University of Cologne

Completed

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Hoffmann-La Roche
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)

Leukemia

France, Australia, Belgium, Italy, Germany, Israel, New Zealand, Czech Republic, Spain, Austria, Denmark
West German Study Group
Roche Pharma AG

Recruiting

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (ADAPT)

Breast Cancer

Germany
German CLL Study Group
Hoffmann-La Roche

Terminated

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (CLLTX1)

Chronic Lymphocytic Leukemia | Richter's Transformation

Germany
Munich Municipal Hospital
German CLL Study Group

Unknown

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Chronic Lymphocytic Leucemia

Germany
West German Study Group
Teva Pharmaceuticals USA

Active, not recruiting

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Early Primary Breast Cancer

Germany
Czech Lymphoma Study Group
Ministry of Health, Czech Republic

Completed

Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy

Mantle Cell Lymphoma
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
Associazione Angela Serra per la ricerca sul cancro
Fondazione Italiana Linfomi ONLUS; INTERNATIONAL T-CELL NON-HODGKIN'S LYMPHOMA...

Completed

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

United States, Korea, Republic of, Spain, Italy, United Kingdom, China, Switzerland, Israel, France, Argentina, Brazil, Chile, Slovakia, Uruguay
Stichting Hemato-Oncologie voor Volwassenen Nederland
German CLL Study Group; Nordic CLL Study Group

Recruiting

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL (AETHER)

CLL/SLL

Netherlands, Denmark, Belgium, Germany
Hoffmann-La Roche
AbbVie; German CLL Study Group

Active, not recruiting

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Spain, France, United Kingdom, Australia, Canada, Denmark, Germany, Italy, Brazil, Argentina, Estonia, New Zealand, Austria, Bulgaria, Croatia, Romania, Russian Federation, Poland, Switzerland, Mexico
German CLL Study Group
Gilead Sciences; Novartis Pharmaceuticals

Completed

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Chronic Lymphocytic Leukemia

Germany

Clinical Trials Sponsored by German Hodgkin's Lymphoma Study Group

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations